- Home
- NAAS vs NCNA Comparison
NAAS vs NCNA Comparison
Compare NAAS & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | NCNA |
|---|---|---|
| Founded | 2019 | 1997 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 7.6M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NAAS | NCNA |
|---|---|---|
| Price | $3.50 | $4.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.6K | ★ 67.8K |
| Earning Date | 03-31-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,817,052.00 | N/A |
| Revenue This Year | $378.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.96 | $2.78 |
| 52 Week High | $40.32 | $330.00 |
Technical Indicators
Market Signals| Indicator | NAAS | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 55.26 |
| Support Level | $3.31 | $4.10 |
| Resistance Level | $3.89 | $4.54 |
| Average True Range (ATR) | 0.26 | 0.30 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 49.82 | 74.59 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.